$CARA News
Last published 1y ago
- 1y agoCARACara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi TherapeuticsGlobeNewswireSTAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that its Board of Directors (the "Board") has approved a 1-for-3 reverse stock split of its
- 1y agoCARACara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock SplitGlobeNewswireSTAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in
- 1y agoCARAHURAVOXXVTSKuehn Law Encourages VOXX, CARA, VTS, and HURA Investors to Contact Law FirmGlobeNewswireNEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 1y agoCARACara Therapeutics and Tvardi Therapeutics Announce Entry into Merger AgreementGlobeNewswireProposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an
- 2y agoCARACara Therapeutics Announces Exploration of Strategic AlternativesGlobeNewswireSTAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced that it has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and
- 2y agoCARACara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia ParestheticaGlobeNewswire– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE
- 2y agoCARACara Therapeutics Reports First Quarter 2024 Financial ResultsGlobeNewswireSTAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 2y agoCARACara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024GlobeNewswireSTAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 2y agoCARACara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswireSTAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 2y agoCARACara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024GlobeNewswireSTAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 2y agoCARALMTContracts for March 5, 2024U.S. Department of WarAIR FORCE General Dynamics Mission Systems Inc., Scottsdale, Arizona, was awarded a $239,300,000 ceiling, indefinite-delivery/indefinite-quantity contract for the U.S. Battlefield Information Collection and Exploitation System, trusted network environment cross domain solution. This contract provides for services to sustain and enhance current coalition operations by providing the capability to sh ...
- 2y agoCARACara Therapeutics, Inc. (CARA) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCARACara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of
- 2y agoCARACara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024GlobeNewswireSTAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to
- 2y agoCARACara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026GlobeNewswire– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce
- 2y agoCARACara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic DermatitisGlobeNewswire– Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus associated with
- 2y agoCARACara Therapeutics Reports Third Quarter 2023 Financial ResultsGlobeNewswire– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all three late-stage oral difelikefalin clinical programs anticipated
- 3y agoCARACara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare RoyaltyGlobeNewswireTransaction supports progression of late-stage oral difelikefalin clinical programs Non-dilutive capital expected to extend cash runway into 2025 STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics,
- 3y agoCARACara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023GlobeNewswireSTAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARACara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis PatientsGlobeNewswireSTAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARACara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireSTAMFORD, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARACara Therapeutics Reports Second Quarter 2023 Financial ResultsGlobeNewswire– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company's share of profit of KORSUVA® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46% increase in
- 3y agoCARACara Therapeutics Appoints Helen M. Boudreau to Board of DirectorsGlobeNewswireSTAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARACara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceGlobeNewswireSTAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARACara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023GlobeNewswireSTAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoAPAMBERYBIGBOOM+44Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600PR NewswireNEW YORK, June 2, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the
- 3y agoCARACara Therapeutics to Present at the Jefferies Healthcare ConferenceGlobeNewswireSTAMFORD, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARACara Therapeutics Reports First Quarter 2023 Financial ResultsGlobeNewswire– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company's share of profit of KORSUVA® (difelikefalin) injection – – Acceleration in demand for KORSUVA injection as evidenced by
- 3y agoCARACara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023GlobeNewswireSTAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARACara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewswireSTAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARACara Therapeutics Releases Inaugural Environmental, Social, and Governance ReportGlobeNewswireSTAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARACara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewswire– 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company's share of profit of KORSUVA® (difelikefalin) injection; FY22 revenue was $41.9 million including collaborative
- 3y agoCARACara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023GlobeNewswireSTAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARACara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of MedicineGlobeNewswireSTAMFORD, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARACara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023GlobeNewswireSTAMFORD, Conn., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARACara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSTAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 3y agoCARAKMPHKemPharm Announces Appointment of Christopher Posner as New Independent DirectorGlobeNewswire24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH)
- 4y agoCARACara Therapeutics Reports Third Quarter 2022 Financial ResultsGlobeNewswire– Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA® (difelikefalin) injection – – Strong demand for KORSUVA injection driven by large dialysis organizations with ~180,000 vials
- 4y agoCARACara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of DirectorsGlobeNewswireSTAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 4y agoCARACara Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSTAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 4y agoCARACara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022GlobeNewswireSTAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from
- 4y agoCARASWKHSWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara TherapeuticsPR NewswireMilestone payment highlights ongoing clinical progress of Oral KORSUVA™ DALLAS, Oct. 10 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH), a life sciences focused specialty finance company catering to
- 4y agoCARACara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in JapanGlobeNewswireSTAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its
- 4y agoCARAIOVARIGLCara Therapeutics Appoints Ryan Maynard as Chief Financial OfficerGlobeNewswireSTAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appo
- 4y agoCARACara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV CongressGlobeNewswire– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Significant reduction of itch intensity was evident at Day 1 and effect was maintained through Week 8 – – Significantl
- 4y agoCARACara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireSTAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Chr
- 4y agoCARACara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022GlobeNewswireSTAMFORD, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Compa
- 4y agoCARACara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV CongressGlobeNewswireSTAMFORD, Conn., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced data from
- 4y agoCARACara Therapeutics Reports Second Quarter 2022 Financial ResultsGlobeNewswire– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin) – – KOMFORT Phase 2
- 4y agoCARACara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth ConferenceGlobeNewswireSTAMFORD, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Chri